Establishment of a CPT-11-resistant human ovarian cancer cell line.

@article{Kijima1994EstablishmentOA,
  title={Establishment of a CPT-11-resistant human ovarian cancer cell line.},
  author={Takashi Kijima and Naohiro Kubota and Kazuto Nishio},
  journal={Anticancer research},
  year={1994},
  volume={14 3A},
  pages={799-803}
}
A camptothecin analog, ((4s)-4,11-diethyl-4-hydroxy-9-[(4- piperidinopiperidino)carbonyloxy]dione hydrochloride trihydrate), (CPT-11), is a recently developed topoisomerase I (Topo I) inhibitor which attracts the attention of clinicians because of its high antitumor activity. We established a CPT-11-resistant human ovarian cell line, HAC2/CPT, from the parental HAC2 cell line. An in vitro drug sensitivity assay revealed that HAC2/CPT was 9.7 and 4.7 times as resistant as HAC2 to CPT-11 and 7… CONTINUE READING